

1 **Airway obstruction, serum vitamin D and mortality in a 33-year follow-up**  
2 **study**

3

4 Tiina Mattila, MD<sup>1,2,3</sup>

5 Tuula Vasankari MD, PhD<sup>4,5</sup>

6 Harri Rissanen, MSc<sup>3</sup>

7 Paul Knekt, PhD<sup>3</sup>

8 Laura Sares-Jäske, MSc<sup>3</sup>

9 Tuija Jääskeläinen, MSc<sup>3</sup>

10 Markku Heliövaara, MD, PhD<sup>3</sup>

11 <sup>1</sup>Department of Pulmonary Diseases, Heart and Lung Center, Helsinki University Hospital,  
12 Meilahti Triangle Hospital, 6<sup>th</sup> floor, PO Box 372, 00029 HUS, Helsinki, Finland.

13 <sup>2</sup>Doctoral Programme in Clinical Research, University of Helsinki, Helsinki, Finland.

14 <sup>3</sup>National Institute for Health and Welfare, PO Box 30, 00271 Helsinki, Finland.

15 harri.rissanen@thl.fi, paul.knekt@thl.fi, laura.sares-jaske@thl.fi, tuija.jaaskelainen@thl.fi,  
16 markku.heliovaara@thl.fi

17 <sup>4</sup>University of Turku, Division of Medicine, Department of Pulmonary Diseases and Clinical  
18 Allergology, Turku University Hospital and University of Turku, PO Box 52 (Hämeentie 11),  
19 20521 Turku, Finland. tuula.vasankari@utu.fi

20 <sup>5</sup>Finnish Lung Health Association (FILHA), Filha ry, Sibeliuksenkatu 11 A 1, 00250  
21 Helsinki, Finland.

22

23 **Correspondence:** Tiina Mattila, Helsinki University Hospital, Department of Pulmonary  
24 Diseases, Meilahti Triangle Hospital, 6<sup>th</sup> floor, PO Box 372, 00029 HUS, Helsinki, Finland.  
25 E-mail: tiina.m.mattila@fimnet.fi, tel: +358 50 361 2512. ORCID ID: 0000-0001-8466-985X

26 **Running head:** Vitamin D, airway obstruction and mortality.

27 **Disclosure statement:** MD Mattila completed study at hand with financial support from the  
28 Hospital District of Helsinki and Uusimaa (a Doctoral Candidate Position in the Doctoral  
29 Programme of Clinical Research at the University of Helsinki / Hospital District of Helsinki  
30 and Uusimaa from June 2016 to December 2017).

31 **Word count:** abstract: 211 words, text: 2641 words, references: 39, tables: 4

32

33

34

35

36

37 **Abstract**

38 **Background and objective:** Chronic obstructive pulmonary disease and low vitamin D status  
39 predict mortality, but their combined effect on mortality remains inconclusive. We aimed to  
40 investigate a joint effect of airway obstruction and vitamin D status on mortality in a  
41 nationally representative cohort.

42 **Methods:** We analysed data of 6676 Finnish adults participating between 1978 and 1980 in a  
43 national health examination survey, undergoing spirometry and having all necessary data  
44 collected. We followed them up in national registers through record linkage until 31  
45 December 2011. We categorised the subjects with obstruction using the lower limit of normal  
46 (LLN) and the measured serum 25-hydroxyvitamin-D (s-25(OH)D) into tertiles.

47 **Results:** Both obstruction and low s-25(OH)D independently predicted mortality in a  
48 multivariate model adjusted also for age, sex, smoking, education, leisure physical activity,  
49 body mass index, asthma and serum C-reactive protein. However, a statistically significant ( $p$   
50 = 0.007) interaction emerged: the adjusted mortality HRs (95% CI's) for s-25(OH)D in  
51 tertiles among the subjects without and with obstruction were 1.00 (lowest), 0.96 (0.87–1.05)  
52 and 0.89 (0.81–0.98); and 1.00, 0.96 (0.71–1.31) and 0.57 (0.40–0.80), respectively.

53 **Conclusions:** In conclusion, obstruction and low s-25(OH)D predict mortality independently  
54 of each other. Our findings suggest that low vitamin D status might be particularly  
55 detrimental among subjects with obstruction.

56 **Introduction**

57 Low vitamin D status and chronic obstructive pulmonary disease (COPD) are common  
58 underdiagnosed conditions worldwide. Inadequate exposure to sunlight and an insufficient  
59 intake from dietary sources induces a low vitamin D status, generally measured as serum 25-  
60 hydroxyvitamin-D (s-25(OH)D) concentrations (<30 nmol/L determined as deficiency). The  
61 prevalence of s-25(OH)D deficiency is currently up to 30% in Europe and 0.6% in Finland,  
62 yet over 30 years ago >20% of our study population suffered from a low s-25(OH)D (1-5). In  
63 COPD, a progressing airway obstruction primarily caused by smoking leads to early death.  
64 Globally, COPD prevalence is 10.1%, falling to 4.3% and 3.1%, respectively, among Finnish  
65 men and women (6-8).

66 Previous studies have shown both associations between COPD and low s-25(OH)D and  
67 between decreasing lung function measures and 25(OH)D concentrations (1,9-11). However,  
68 the link between COPD and vitamin D metabolism remains unconfirmed. As such, a low s-  
69 25(OH)D evidently plays a role in regulating inflammatory reactions in COPD (1,3,12). Low  
70 s-25(OH)D and COPD are associated with similar factors, such as ageing, a low  
71 socioeconomic status, smoking, physical inactivity and chronic diseases (1,3,6,13,14). Yet,  
72 limited longitudinal data exist on the association between COPD and low s-25(OH)D (12).

73 Low s-25(OH)D and COPD predict premature death—COPD by decreasing lung function and  
74 the s-25(OH)D by decreasing concentration (6,13-18). Whether low s-25(OH)D has a similar  
75 or different association with mortality in subjects with COPD than in general population  
76 remains less studied and inconclusive (19-21).

77 Thus, we aimed to analyse whether a low s-25(OH)D confounds or modifies the association  
78 between airway obstruction and mortality during a long follow-up.

79

## 80 **Material and methods**

81

### 82 *Study population*

83 The Mini-Finland Health Survey, a population-based nationally representative health  
84 examination survey, consists of a two-stage cluster performed between 1978 and 1980 (22). In  
85 all 40 nationally representative areas with 40 000 to 60 000 subjects living on them were  
86 selected for inclusion in the first stage; and a representative sample of Finnish adults (3637  
87 men and 4363 women) aged 30 to 91 from each area was selected from the population register  
88 in the second stage. Each subject in the population of each area had an equal probability for  
89 selection (probability proportional to size sampling). From this sample, 7217 (90%) subjects  
90 participated in the survey. Our study included 6676 subjects (3091 men and 3585 women) for  
91 whom was collected all relevant health information and who underwent a comprehensive  
92 health examination, including spirometry (22-25).

93

### 94 *Measurements and definition of determinants*

95 Laboratory technicians with special training performed spirometry using a Vitalograph  
96 spirometer (Vitalograph Ltd., Buckingham, England) following standard guidelines and  
97 instructions. Technicians presented the test procedure individually to each subject. Ideally,  
98 each participant produced minimum two spirometry curves, as consistent as possible, reaching  
99 an adequate and high-quality forced expiratory volume in 1 s (FEV<sub>1</sub>) and forced vital capacity  
100 (FVC). The FEV<sub>1</sub>/FVC was determined using the highest readings for FEV<sub>1</sub> and FVC from

101 the technically acceptable measurements for the air temperature and pressure, saturated with  
102 water vapour (BTPS) values (spirometry technique used in Mini-Finland Health Survey).  
103 Spirometry was performed without bronchodilation (22,23,25).

104 Individual lung function results were calculated using the Global Lung Function Initiative  
105 (GLI) reference values which were derived from the spirometry records of 97,759 multi-  
106 ethnic, healthy non-smokers aged 3 to 95. The GLI reference values were determined for four  
107 separate ethnic groups, and we only applied the reference values for Caucasians. Subjects  
108 with FEV<sub>1</sub>/FVC values below the lower limit of normal (LLN) using reference values were  
109 classified as having airway obstruction while others did not have obstruction (26,27).

110 Height and weight were measured. Body mass index (BMI) (weight (kg)/height<sup>2</sup> (m<sup>2</sup>)) was  
111 used as a measure of relative weight. Age, sex, leisure physical activity and educational levels  
112 were collected through a basic questionnaire. Leisure physical activity was determined  
113 through questions on the frequency, intensity and duration of physical activity and further  
114 categorized as inactive (little physical exercise), occasionally active (exercise alongside some  
115 hobbies or irregular exercise) and regularly active (regular exercise). The completed number  
116 of years of schooling classified educational levels in basic (<8 years), intermediate (8–12  
117 years) and higher (>12 years) (22-25).

118 A standard interview inquired smoking habits, and these were categorized as never, former  
119 and current smokers. Former smokers had quit smoking minimum one month before the  
120 baseline survey. All subjects who had smoked at least one pipe, cigar or cigarette daily or  
121 almost daily during the year before the survey were categorised as current smokers. Current  
122 smokers were further categorized into two groups based on the number of daily smoked  
123 cigarettes: 1 to 19 and  $\geq 20$  cigarettes (22-25).

124 Fasting blood samples were taken during the health examination and stored frozen at  $-20^{\circ}\text{C}$ .  
125 s-25(OH)D concentration was determined in 2003 using radioimmunoassay (DiaSorin, Inc.,  
126 Stillwater, Minnesota, USA). The inter-assay coefficient of variation for s-25(OH)D  
127 determination was 7.80% at a mean level of 47.3 nmol/L ( $n = 167$ ) and 9.12% at 131.3  
128 nmol/L ( $n = 135$ ). The proportion of quality-control samples was 13.5% (5,28). In this study,  
129 no single cut-off limit was used to define low s-25(OH)D. We classified s-25(OH)D  
130 concentrations into tertiles: 5–32 nmol/L, 33–48 nmol/L and 49–180 nmol/L; the  
131 concentrations approximated international definitions for vitamin D deficiency ( $<30$  nmol/L)  
132 and insufficiency (30–49.9 nmol/L) (4).

133 In Finland, situated geographically between the latitudes  $60^{\circ}\text{N}$  and  $70^{\circ}\text{N}$ , biologically  
134 effective ultraviolet B irradiation producing vitamin D through the skin by sunshine is only  
135 possible during the summer months. When our baseline study was performed, s-25(OH)D  
136 concentrations were higher between May and October (2,5). Yet, baseline examinations were  
137 conducted during different seasons. Therefore, we divided subjects into two seasonal groups:  
138 winter (November–April) and summer (May–October).

139 Serum C-reactive protein (CRP) concentration was determined between 2003 and 2005 using  
140 a latex turbido-metric immunoassay (Olympus AU 400 analyser system for clinical chemistry,  
141 Wako Chemicals, Neuss, Germany), at a detection limit of 0.06 mg/L. The measured CRP  
142 levels were categorised as 0.04–0.99 mg/L, 1.00–1.99 mg/L and  $\geq 2.00$  mg/L (22,24).

143 Subject's chronic disease history and their overall health status was inquired in the basic  
144 questionnaire. For those subjects who had any abnormal findings from the examination or  
145 questionnaires, a specially trained physician performed a standardised physical examination  
146 (22-24). The physician diagnosed asthma on the basis of medical history, symptoms and  
147 physical status applying preset criteria (22-25).

148

149 *Follow-up*

150 We continuously followed mortality from Statistics Finland using the subjects' individual  
151 identification numbers to track participants from baseline examination through 31 December  
152 2011 (29).

153

154 *Statistical analysis*

155 We constructed our models to analyse associations between obstruction and low s-25(OH)D  
156 primarily based on previous Finnish publications. As such, we previously analysed factors  
157 which were associated with obstruction in the same population sample (25) and others with s-  
158 25(OH)D in another Finnish data set (30,31). Factors which were associated with obstruction  
159 and s-25(OH)D previously included age, education (in years), leisure physical activity, BMI  
160 and smoking history. In addition, CRP and sex were associated with obstruction and s-  
161 25(OH)D in this material, and a history of asthma represented a possible confounding factor  
162 for obstruction. All these variables appeared relevant to our study; thus, we included them all  
163 in our analysis here. Additionally, we analysed the modifying effect of season of s-25(OH)D  
164 blood sampling (5,30,31).

165 We analysed the cross-sectional associations between obstruction and baseline characteristics  
166 using logistic regression, expressing results as model-adjusted odds ratios (ORs) with 95%  
167 confidence intervals (CIs). We analysed the strength of the associations of obstruction and s-  
168 25(OH)D with mortality in the cohort study design using Cox's proportional hazards  
169 regression model. The results were expressed as model-adjusted hazard ratios (HRs) with  
170 95% CIs. We constructed three main models: adjusting for age and sex (1); further for



171 smoking (2); and finally also for leisure physical activity, education, BMI, asthma and serum  
172 C-reactive protein (3, multivariate model), which were also considered potential confounding  
173 factors. Whether s-25(OH)D, season of blood sample collection and obstruction modified the  
174 effects of each other were examined by entering their first-degree interaction terms into the  
175 multivariate models. Statistical significance was tested using the likelihood ratio test. Finally,  
176 to explore the proportional hazards assumption of the Cox's model and to test the adequacy of  
177 the long follow-up, we compared the results from the full model between the follow-up times  
178 of 0–10 years, 11–20 years and >20 years from baseline. In addition, we also restricted the  
179 follow-up experience to the years 2005 to 2011 to explore influence of the fortification of  
180 food with vitamin D that was introduced in Finland in 2003. We analysed s-25(OH)D as both  
181 categorical (tertiles) and ordinary-scaled variables throughout the study. All analyses were  
182 performed using SAS System for Windows (version 9.3, SAS Institute, Inc., Cary, NC, USA)  
183 and IBM's SPSS (version 24).

184

#### 185 *Ethical considerations*

186 The Mini-Finland Health Survey predated current legislation on ethics in medical research.  
187 However, all participants were fully informed about the study, participated voluntarily and the  
188 use of their information for medical research was explained to them. Agreeing to participate  
189 in the baseline health examination was considered informed consent. Statistics Finland  
190 approved the linkage of national mortality data to the survey data used here (29).

191 This study does not fall under the purview of laws regarding medical research, thus, the study  
192 protocol does not violate any ethical considerations or standards, according to a statement

193 from the Medical Ethics Committee of the Hospital District of Helsinki and Uusimaa in  
194 Finland (June 2013).

195

## 196 **Results**

197 Table 1 presents the baseline characteristics and their prevalence. At baseline, the cohort  
198 included 311 (4.7%) subjects with obstruction. Mean FEV<sub>1</sub> was 2.1 l/s (standard deviation  
199 (SD) 1.0) in obstructive and 3.3 l/s (SD 1.0) in non-obstructive subjects, while mean  
200 concentrations of s-25(OH)D reached 39.1 nmol/L (SD 18.8) and 43.6 nmol/L (SD 19.5),  
201 respectively.

202 We found an inverse association between obstruction and s-25(OH)D (Table 1). The season  
203 of blood sample collection did not modify that association (p=0.68 for the interaction).

204 By the end of 2011, 3530 (52.9%) deaths in the study population occurred, while 247 (79.4%)  
205 of the subjects with obstruction died. Obstruction and low s-25(OH)D independent of one  
206 another predicted mortality (Table 2). HR (95% CI) for the subjects with obstruction was 1.46  
207 (1.28–1.68) when those without obstruction were used as the reference, while for s-25(OH)D  
208 from the lowest to highest tertile, HRs were 1 (reference), 0.92 (0.85–1.00) and 0.84 (0.78–  
209 0.92), respectively. Low s-25(OH)D did not confound the association between obstruction  
210 and mortality (Table 3).

211 A statistically significant interaction (p=0.007) emerged between obstruction and s-25(OH)D  
212 tertiles when entered as a categorical variable: among subjects with obstruction HR (95% CI)  
213 was 0.57 (0.40–0.80) in the third tertile, whereas among those without obstruction the  
214 corresponding HR was 0.89 (0.81–0.98) (Table 4). The season of blood sample collection did

215 not further modify or confound the associations of obstruction and s-25(OH)D with mortality  
216 (data not shown).

217 Finally, we used multivariate models to analyse the follow-up time strata of 0–10 years, 11–  
218 20 years and >20 years from baseline. The primary findings remained largely unchanged (data  
219 not shown). However, when the follow-up experience was restricted to the years 2005 to 2011  
220 (21 deaths in 85 subjects with airway obstruction), the baseline s-25(OH)D did not anymore  
221 predict mortality (p-value for trend 0.32); HRs from the lowest to highest tertile were 1  
222 (reference), 0.90 (0.76–1.07) and 0.88 (0.74–1.05), respectively.

223

## 224 **Discussion**

225 In our study airway obstruction and low s-25(OH)D independent of each other predicted  
226 mortality during the follow-up of 33 years. However, the association between low s-25(OH)D  
227 and mortality was stronger in those with obstruction than others.

228 In accordance with previous studies, we observed an inverse cross-sectional association  
229 between obstruction and s-25(OH)D, which was partly explained by other factors. COPD is  
230 evidently associated with low s-25(OH)D (1,9-11,14). Previously, vitamin D supplementation  
231 improved lung functions among ever-smokers with vitamin D-deficiency or COPD and  
232 decreased COPD exacerbations (32,33). Yet, the association between COPD and low s-  
233 25(OH)D is complex, multiple factors tend to confound it and previous findings appear  
234 contradictory (1,12). COPD and low s-25(OH)D have both shown associations with both  
235 chronic diseases and many factors predicting morbidity, such as ageing, smoking and reduced  
236 physical activity (1,3,6,13,30,34,35). Furthermore, low s-25(OH)D and s-25(OH)D

237 metabolites might affect COPD pathophysiology and co-morbidities, such as osteoporosis,  
238 cardiovascular diseases and respiratory infections (1,3,12,20).

239 In our study obstruction and low s-25(OH)D predicted mortality independently of each other  
240 and independently of other confounding factors. Comparisons of the results between previous  
241 studies and the present one are difficult because of the wealth of factors discussed above  
242 (1,3,6,12,13,30,34,35). In two studies with follow-up times from 10 to 14 years, low s-  
243 25(OH)D did not predict mortality among subjects with obstruction (19,20). Another study  
244 adjusted for common cardiovascular risk factors revealed an association between low s-  
245 25(OH)D and mortality among those with normal lung function (19). In a third study with an  
246 18-year follow-up, low s-25(OH)D predicted mortality among the subjects with obstruction;  
247 however, this resulted primarily from the higher age and more negative cardiovascular risk  
248 factor profile of those with a low s-25(OH)D (21). In that study, the cut-off limit for the  
249 lowest s-25(OH)D tertile was <50.9 nmol/L which was much higher than our cut-off limit of  
250 <33 nmol/L.

251 In our study the association between low s-25(OH)D and mortality appeared pronounced  
252 among the subjects with obstruction. Albeit statistically significant, this interaction may  
253 result from chance alone because of small numbers of subjects. Nevertheless, if replicated in  
254 future studies, intervention trials and therapeutic implications may prove justified.

255 Our study's strength lies in its continuous 33-year follow-up of a population sample  
256 representing adult Finns from a national health examination survey with a 90% participation  
257 rate (22,23). Specially trained expert professionals performed examinations using  
258 standardised methods (22-24). The causes and dates of death were obtained from death  
259 certificates signed by the physicians responsible for their care (22,29). An additional strength  
260 lies in the naturally low s-25(OH)D in our study population; when the baseline survey was

261 executed, no vitamin D fortification was used and working outside in summertime under the  
262 sun remained common (22,23). The use of vitamin D supplements complicates and confounds  
263 analyses in newer datasets (1,3,12,30) whereas it rarely appeared among Finnish adults at the  
264 time of our baseline survey. In addition, the concentration of s-25(OH)D remains stable in  
265 long-term stored blood samples (36), although the 20 years between blood sampling and  
266 analyses might affect the s-25(OH)D concentrations measured.

267 The small sample size is the primary limitation in our study—our material carried no  
268 statistical power for more specific analyses. Therefore, such topics as the specific causes of  
269 death and degree of obstruction remain unanalysed. This same material resulted in previous  
270 publications regarding the influence of obstruction and s-25(OH)D, respectively, on  
271 cardiovascular and coronary mortality and the severity of obstruction and all-cause mortality  
272 (5,25,37). In addition, no bronchodilation test was performed; thus, we maybe have,  
273 incorrectly, categorised some reversible obstructions as chronic. Unfortunately, we had no  
274 data about COPD's exacerbations and could, therefore, not consider this possible confounder.  
275 Additionally, no absolute definitions for COPD, obstruction or low s-25(OH)D exist, although  
276 clinicians use definitions and cut-off limits for both (2,4,6,27). Therefore, the results from  
277 studies (this and others) may not be directly comparable, a problem previously observed  
278 (3,10,37). There is remarkable seasonal and other variation in s-25(OH)D levels (38) but,  
279 unfortunately, only one blood sample was taken in our study. An additional limitation appears  
280 in the markedly improved s-25(OH)D among Finns between 2000 and 2011 resulting from  
281 the vitamin D fortification policy initiated after 2003 (2) and changes in smoking habits.  
282 However, the prevalence of obstruction remained unchanged in Finland between the Mini-  
283 Finland (1978–1980) and Health 2000 Surveys (7,39). Furthermore, other baseline

284 characteristics may have changed during follow-up exerting some influence on our results.  
285 This limitation typically accompanies cohort studies.

286

## 287 **Conclusions**

288 In conclusion, airway obstruction and low s-25(OH)D independently predict mortality; an  
289 outcome which a physician should consider when treating high-risk groups. If not replicated  
290 in future, the interaction we found for obstruction and low s-25(OH)D upon mortality does  
291 not justify causal inference.

292

## 293 **Acknowledgments**

294 The University of Helsinki / Hospital District of Helsinki and Uusimaa awarded to the first  
295 author a Doctoral Candidate Position (from June 2016 to December 2017) which allowed for  
296 the write-up of our analysis.

297

## 298 **Conflict of Interest**

299 MD Mattila completed this study through financial support from the Hospital District of  
300 Helsinki and Uusimaa (a Doctoral Candidate Position in the Doctoral Programme of Clinical  
301 Research at the University of Helsinki / Hospital District of Helsinki and Uusimaa from June  
302 2016 to December 2017). MD Vasankari, MSc Rissanen, PhD Knekt, MSc Sares-Jäske, MSc  
303 Jääskeläinen and MD Heliövaara declare no potential conflict of interest.

304

305 **Funding**

306 The University of Helsinki / Hospital District of Helsinki and Uusimaa awarded to the first  
307 author a doctoral candidate position from June 2016 to December 2017.

308 **References:**

309

- 310 (1) Kokturk N, Baha A, Oh YM, Young Ju J, Jones PW. Vitamin D deficiency: What does it  
311 mean for chronic obstructive pulmonary disease (COPD)? a comprehensive review for  
312 pulmonologists. *Clin Respir J* 2016 December 07.
- 313 (2) Jaaskelainen T, Itkonen ST, Lundqvist A, Erkkola M, Koskela T, Lakkala K, et al. The  
314 positive impact of general vitamin D food fortification policy on vitamin D status in a  
315 representative adult Finnish population: evidence from an 11-y follow-up based on  
316 standardized 25-hydroxyvitamin D data. *Am J Clin Nutr* 2017 June 01;105(6):1512-1520.
- 317 (3) Quint JK, Wedzicha JA. Is vitamin D deficiency important in the natural history of  
318 COPD? *Thorax* 2010 March 01;65(3):192-194.
- 319 (4) Institute of Medicine Food and Nutrition Board. Dietary reference intakes for adequacy:  
320 calcium and vitamin D. National Academies Press: Washington (DC), USA, 2011.
- 321 (5) Kilkinen A, Knekt P, Aro A, Rissanen H, Marniemi J, Heliovaara M, et al. Vitamin D  
322 status and the risk of cardiovascular disease death. *Am J Epidemiol* 2009 October  
323 15;170(8):1032-1039.
- 324 (6) Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global  
325 Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung  
326 Disease 2017 Report: GOLD Executive Summary. *Eur Respir J* 2017 March 06;49(3):2017.  
327 Print 2017 Mar.
- 328 (7) Vasankari TM, Impivaara O, Heliovaara M, Heistaro S, Liippo K, Puukka P, et al. No  
329 increase in the prevalence of COPD in two decades. *Eur Respir J* 2010 October 01;36(4):766-  
330 773.
- 331 (8) Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al.  
332 International variation in the prevalence of COPD (the BOLD Study): a population-  
333 based prevalence study. *Lancet*. 2007 Sep 1;370(9589):741-50.
- 334
- 335 (9) Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buyschaert I, et al. Vitamin  
336 D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-  
337 binding gene. *Thorax* 2010 March 01;65(3):215-220.
- 338 (10) Zhu M, Wang T, Wang C, Ji Y. The association between vitamin D and COPD risk,  
339 severity, and exacerbation: an updated systematic review and meta-analysis. *Int J Chron*  
340 *Obstruct Pulmon Dis* 2016 October 19;11:2597-2607.



341 (11) Afzal S, Lange P, Bojesen SE, Freiberg JJ, Nordestgaard BG. Plasma 25-hydroxyvitamin  
342 D, lung function and risk of chronic obstructive pulmonary disease. *Thorax* 2014 January  
343 01;69(1):24-31.

344 (12) Janssens W, Decramer M, Mathieu C, Korf H. Vitamin D and chronic obstructive  
345 pulmonary disease: hype or reality? *Lancet Respir Med* 2013 December 01;1(10):804-812.

346 (13) Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, et al. Comorbidity,  
347 systemic inflammation and outcomes in the ECLIPSE cohort. *Respir Med* 2013 September  
348 01;107(9):1376-1384.

349 (14) Khaw KT, Luben R, Wareham N. Serum 25-hydroxyvitamin D, mortality, and incident  
350 cardiovascular disease, respiratory disease, cancers, and fractures: a 13-y prospective  
351 population study. *Am J Clin Nutr* 2014 November 01;100(5):1361-1370.

352 (15) Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency  
353 and mortality risk in the general population: a meta-analysis of prospective cohort studies.  
354 *Am J Clin Nutr* 2012 January 01;95(1):91-100.

355 (16) Baughman P, Marott JL, Lange P, Martin CJ, Shankar A, Petsonk EL, et al. Combined  
356 effect of lung function level and decline increases morbidity and mortality risks. *Eur J*  
357 *Epidemiol* 2012 December 01;27(12):933-943.

358 (17) Ford ES, Zhao G, Tsai J, Li C. Vitamin D and all-cause mortality among adults in USA:  
359 findings from the National Health and Nutrition Examination Survey Linked Mortality Study.  
360 *Int J Epidemiol* 2011 August 01;40(4):998-1005.

361 (18) Gaksch M, Jorde R, Grimnes G, Joakimsen R, Schirmer H, Wilsgaard T, et al. Vitamin D  
362 and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D  
363 in 26916 individuals from a European consortium. *PLoS One* 2017 February  
364 16;12(2):e0170791.

365 (19) Ford ES. Lung function, 25-hydroxyvitamin D concentrations and mortality in US adults.  
366 *Eur J Clin Nutr* 2015 May 01;69(5):572-578.

367 (20) Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Fruekilde PB, Pedersen SS, et al.  
368 Serum vitamin D in patients with chronic obstructive lung disease does not correlate with  
369 mortality--results from a 10-year prospective cohort study. *PLoS One* 2013;8(1):e53670.

370 (21) Lee HM, Liu M, Lee K, Luo Y, Wong ND. Does low vitamin D amplify the association  
371 of COPD with total and cardiovascular disease mortality? *Clin Cardiol* 2014 August  
372 01;37(8):473-478.

373 (22) National Institute for Health and Welfare in Finland. Available at:  
374 [https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/population-studies/finnish-](https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/population-studies/finnish-mobile-clinic/mini-finland-health-survey)  
375 [mobile-clinic/mini-finland-health-survey](https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/population-studies/finnish-mobile-clinic/mini-finland-health-survey). Accessed: October 25, 2017.

376 (23) Aromaa A, Heliövaara M, Impivaara O, et al. Health, functional limitations and need for  
377 care in Finland. Basic results from the Mini-Finland Health Survey (in Finnish with English

- 378 Summary). Publications of the Social Insurance Institution 1989. Helsinki and Turku.  
379 Available at: <http://hdl.handle.net/10138/162843>. Accessed: October 25 2017.
- 380 (24) Aromaa A, Heliövaara M, Knekt P, Reunanen A, Impivaara O, Maatela J. Cardiovascular  
381 and respiratory survey methods. Part 2 (in Finnish with English summary). Publications of the  
382 Social Insurance Institution 1985. Helsinki and Turku. Available at:  
383 <http://hdl.handle.net/10138/162384>. Accessed: October 25 2017.
- 384 (25) Mattila T, Vasankari T, Kanervisto M, Laitinen T, Impivaara O, Rissanen H, et al.  
385 Association between all-cause and cause-specific mortality and the GOLD stages 1-4: A 30-  
386 year follow-up among Finnish adults. *Respir Med* 2015 August 01;109(8):1012-1018.
- 387 (26) Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative  
388 strategies for lung function tests. *Eur Respir J* 2005 November 01;26(5):948-968.
- 389 (27) Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic  
390 reference values for spirometry for the 3-95-yr age range: the global lung function 2012  
391 equations. *Eur Respir J* 2012 December 01;40(6):1324-1343.
- 392 (28) Konstari S, Paananen M, Heliövaara M, Knekt P, Marniemi J, Impivaara O, et al.  
393 Association of 25-hydroxyvitamin D with the incidence of knee and hip osteoarthritis: a 22-  
394 year follow-up study. *Scand J Rheumatol* 2012 March 01;41(2):124-131.
- 395 (29) Statistics Finland. Causes of deaths. Available at: [http://www.stat.fi/index\\_en.html](http://www.stat.fi/index_en.html),  
396 [http://www.stat.fi/til/ksyyt/2005/ksyyt\\_2005\\_2006-10-31\\_luo\\_002.html](http://www.stat.fi/til/ksyyt/2005/ksyyt_2005_2006-10-31_luo_002.html). Accessed: 2011.
- 397 (30) Jaaskelainen T, Knekt P, Marniemi J, Sares-Jaske L, Mannisto S, Heliövaara M, et al.  
398 Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health.  
399 *Eur J Nutr* 2013 March 01;52(2):513-525.
- 400 (31) Virtanen JK, Nurmi T, Voutilainen S, Mursu J, Tuomainen TP. Association of serum 25-  
401 hydroxyvitamin D with the risk of death in a general older population in Finland. *Eur J Nutr*  
402 2011 August 01;50(5):305-312.
- 403 (32) Sluyter JD, Camargo CA, Waayer D, Lawes CMM, Toop L, Khaw KT, et al. Effect of  
404 Monthly, High-Dose, Long-Term Vitamin D on Lung Function: A Randomized Controlled  
405 Trial. *Nutrients* 2017 December 13;9(12):10.3390/nu9121353.
- 406 (33) Zendedel A, Gholami M, Anbari K, Ghanadi K, Bachari EC, Azargon A. Effects of  
407 Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study.  
408 *Glob J Health Sci* 2015 January 14;7(4):243-248.
- 409 (34) World Health Organization WHO. Noncommunicable diseases and mental health.  
410 Available at: [http://www.who.int/nmh/events/ncd\\_action\\_plan/en](http://www.who.int/nmh/events/ncd_action_plan/en). Accessed: October 25,  
411 2017.
- 412 (35) Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJ, Kromhout D. Prevalence of  
413 morbidity and multimorbidity in elderly male populations and their impact on 10-year all-

- 414 cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). *J Clin Epidemiol* 2001  
415 July 01;54(7):680-686.
- 416 (36) Agborsangaya C, Toriola AT, Grankvist K, Surcel HM, Holl K, Parkkila S, et al. The  
417 effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D  
418 and androstenedione. *Nutr Cancer* 2010;62(1):51-57.
- 419 (37) Mattila T, Vasankari T, Rissanen H, Knekt P, Puukka P, Heliovaara M. Airway  
420 obstruction and the risk of myocardial infarction and death from coronary heart disease: a  
421 national health examination survey with a 33-year follow-up period. *Eur J Epidemiol* 2017  
422 July 07.
- 423 (38) Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of  
424 serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12  
425 months in an intervention study. *Am J Epidemiol* 2010 April 15;171(8):903-908.
- 426 (39) Jousilahti P, Borodulin K. Suomalaisten tupakointi vähenee. Tutkimuksesta tiiviisti 3 (in  
427 Finnish). Publications of the National Institute for Health and Welfare: Helsinki, Finland,  
428 2012.
- 429

**Table 1**Baseline characteristics and their associations with airway obstruction (FEV<sub>1</sub>/FVC below LLN) in the study population from the logistic regression analyses

Characteristics		Total (n)	Obstruction (n) <sup>1</sup>	OR <sup>2</sup>	95% CI	OR <sup>3</sup>	95% CI
Vitamin D status <sup>4</sup>	First tertile (5–32 nmol/L)	2177	131	1		1	
	Second tertile (33–48 nmol/L)	2284	101	0.79	0.59–1.08	0.93	0.70–1.23
	Third tertile (49–180 nmol/L)	2215	79	0.61	0.44–0.85	0.75	0.55–1.02
p (for trend)				0.001		0.07	
Age (in years)	Mean 50.5, SD ± 13.7 <sup>5</sup>		311	1.67	1.50–1.88	1.66	1.45–1.89
p (for trend)				<0.001		<0.001	
Sex	Male	3091	207	1		1	
	Female	3585	104	0.38	0.30–0.48	0.58	0.43–0.79
p (for heterogeneity)				<0.001		<0.001	
Smoking	Never smoker	3690	92	1		1	
	Former smoker	1388	79	2.03	1.43–2.88	2.20	1.54–3.15
	Current smoker, 1–19 cigarettes/day	991	83	3.90	2.77–5.48	3.42	2.39–4.90
	Current smoker, ≥20 cigarettes/day	607	57	4.81	3.23–7.17	4.41	2.91–6.70
p (for heterogeneity)				<0.001		<0.001	
Asthma	No	6558	280	1		1	
	Yes	118	31	8.82	5.65–13.78	11.43	7.11–18.36
p (for heterogeneity)				<0.001		<0.001	
Leisure physical activity	Inactive	2349	155	1		1	
	Occasionally active	3279	133	0.65	0.51–0.82	0.78	0.61–1.01
	Regularly active	1048	23	0.36	0.23–0.57	0.51	0.32–0.82
p (for heterogeneity)				<0.001		0.009	
Educational level	Basic	4480	261	1		1	
	Intermediate	1431	33	0.48	0.33–0.70	0.51	0.35–0.75
	Higher	765	17	0.49	0.30–0.82	0.56	0.33–0.94
p (for heterogeneity)				<0.001		<0.001	
BMI	<20	310	32	1		1	
	20–24.99	2733	135	0.39	0.26–0.59	0.43	0.27–0.67
	25–29.99	2632	105	0.26	0.17–0.40	0.28	0.18–0.45
	30–34.99	826	32	0.26	0.15–0.44	0.26	0.15–0.45
	≥35	175	7	0.35	0.15–0.82	0.32	0.13–0.78
p (for trend)				<0.001		<0.001	
CRP <sup>6</sup>	0.04–0.99 mg/L	3180	107	1		1	
	1–1.99 mg/L	1528	77	1.26	0.93–1.71	1.22	0.89–1.68
	≥2.00 mg/L	1968	127	1.43	1.09–1.88	1.16	0.86–1.55
p (for trend)				0.01		0.35	

<sup>1</sup> FEV<sub>1</sub>/FVC below LLN.<sup>2</sup> Odds ratio (OR) with 95% confidence intervals (CIs), age adjusted for sex, sex adjusted for age and the other factors adjusted for age and sex.<sup>3</sup> OR with 95% CIs in a multivariate model adjusted for all factors listed in this table.<sup>4</sup> Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles<sup>5</sup> SD, standard deviation; range 61, 30–91 years.<sup>6</sup> Concentration of C-reactive protein.

**Table 2**

Associations between baseline characteristics and mortality from 1978–1980 through 31 December 2011

Characteristics		Deaths (n)	HR <sup>1</sup>	95% CI	HR <sup>2</sup>	95% CI
Obstruction <sup>3</sup>	No	3283	1		1	
	Yes	247	1.68	1.48–1.92	1.46	1.28–1.68
p (for heterogeneity)			<0.001		<0.001	
Vitamin D status <sup>4</sup>	First tertile (5–32 nmol/L)	1331	1		1	
	Second tertile (33–48 nmol/L)	1165	0.89	0.82–0.96	0.92	0.85–1.00
	Third tertile (49–180 nmol/L)	1034	0.77	0.71–0.84	0.84	0.78–0.92
p (for trend)			<0.001		<0.001	
Age	Years, $\pm 1$ SD	Mean 59.0, SD $\pm 12.2$ , Range 61 <sup>5</sup>	4.42	4.23–4.63	4.49	4.28–4.71
p (for trend)			<0.001		<0.001	
Sex	Male	1759	1		1	
	Female	1771	0.54	0.51–0.58	0.63	0.58–0.68
p (for heterogeneity)			<0.001		<0.001	
Smoking	Never smoker	1845	1		1	
	Former smoker	748	1.12	1.02–1.23	1.12	1.01–1.23
	Current smoker, 1–19 cigarettes/day	563	1.86	1.68–2.06	1.72	1.55–1.91
	Current smoker, $\geq 20$ cigarettes/day	374	2.73	2.41–3.09	2.35	2.06–2.67
p (for heterogeneity)			<0.001		<0.001	
Asthma	No	3456	1		1	
	Yes	74	1.05	0.83–1.32	0.95	0.75–1.20
p (for heterogeneity)			0.70		0.68	
Leisure physical activity	Inactive	1498	1		1	
	Occasionally active	1623	0.78	0.72–0.83	0.87	0.81–0.94
	Regularly active	409	0.69	0.62–0.77	0.87	0.78–0.98
p (for heterogeneity)			<0.001		<0.001	
Educational level	Basic	2750	1		1	
	Intermediate	559	0.87	0.79–0.95	0.92	0.84–1.01
	Higher	221	0.68	0.59–0.78	0.73	0.64–0.84
p (for heterogeneity)			<0.001		<0.001	
BMI	<20	138	1		1	
	20–24.9	1174	0.59	0.50–0.71	0.63	0.53–0.75
	25–29.9	1514	0.61	0.51–0.72	0.65	0.54–0.78
	30–34.9	576	0.74	0.62–0.90	0.74	0.61–0.89
	$\geq 35$	128	0.86	0.68–1.10	0.78	0.61–1.00
p (for trend)			0.005		0.196	
CRP <sup>6</sup>	0–0.99 mg/L	1234	1		1	
	1–1.99 mg/L	913	1.22	1.12–1.33	1.15	1.05–1.26
	$\geq 2$ mg/L	1383	1.67	1.54–1.80	1.46	1.35–1.59
p (for trend)			<0.001		<0.001	

<sup>1</sup> Hazard ratio (HR) with 95% confidence intervals (CIs), age adjusted for sex, sex adjusted for age and other factors adjusted for age and sex.<sup>2</sup> HR with 95% CIs in a multivariate model adjusted for all factors listed in this table.<sup>3</sup> FEV<sub>1</sub>/FVC over or below LLN.<sup>4</sup> Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles.

<sup>5</sup> SD, standard deviation; range 30–91 years.

<sup>6</sup> Concentration of C-reactive protein.

432

**Table 3**

Association between airway obstruction (FEV<sub>1</sub>/FVC below LLN) and mortality<sup>1</sup> in variously adjusted models from 1978–1980 through 31 December 2011

Model adjusted for		HR <sup>2</sup>	95% CI
Age and sex	No obstruction <sup>3</sup>	1	
	Obstruction <sup>3</sup>	1.69	1.49–1.93
Age, sex, vitamin D status <sup>4</sup>	No obstruction <sup>3</sup>	1	
	Obstruction <sup>3</sup>	1.68	1.48–1.92
Age, sex, smoking history	No obstruction <sup>3</sup>	1	
	Obstruction <sup>3</sup>	1.53	1.34–1.74
Age, sex, smoking history, vitamin D status <sup>4</sup>	No obstruction <sup>3</sup>	1	
	Obstruction <sup>3</sup>	1.52	1.33–1.73
Full model <sup>5</sup> , without vitamin D status <sup>4</sup>	No obstruction <sup>3</sup>	1	
	Obstruction <sup>3</sup>	1.46	1.27–1.67
Full model <sup>5</sup> with vitamin D status <sup>4</sup>	No obstruction <sup>3</sup>	1	
	Obstruction <sup>3</sup>	1.46	1.28–1.67

<sup>1</sup> There were 3283 deaths in subjects without obstruction and 247 in those with obstruction.

<sup>2</sup> Hazard ratio (HR) with 95% confidence intervals (CIs).

<sup>3</sup> FEV<sub>1</sub>/FVC over or below LLN.

<sup>4</sup> Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles.

<sup>5</sup> Multivariate model adjusted for age, sex, smoking, obstruction, asthma, education (in years), leisure physical activity, BMI and CRP.

434 **Table 4**

435 Association between airway obstruction (FEV<sub>1</sub>/FVC below LLN), vitamin D status and mortality from 1978–1980 through 31 December 2011

Characteristics	No obstruction				Obstruction			
	Total (n)	Deaths (n)	HR <sup>2</sup>	95% CI	Total (n)	Deaths (n)	HR <sup>2</sup>	95% CI
Vitamin D status <sup>1</sup>								
First tertile (5–32 nmol/L)	2046	1220	1		131	111	1	
Second tertile (33–48 nmol/L)	2183	1083	0.96	0.87–1.05	101	82	0.96	0.71–1.31
Third tertile (49–180 nmol/L)	2136	980	0.89	0.81–0.98	79	54	0.57	0.40–0.80
p-value for trend				0.002				0.002
p-values for interactions ‘obstruction*vitamin D status’								
Vitamin D status as an ordinary scaled variable:				0.02				
Vitamin D status as a categorical variable:				0.007				

<sup>1</sup> Concentration of 25-hydroxyvitamin D (25(OH)D).

<sup>2</sup> HR with 95% CIs in multivariate model adjusted for age, sex, smoking, obstruction, asthma, education (in years), leisure physical activity, BMI and CRP.

437